MYSTIC program: summary of European data from 1997 to 2000.

MYSTIC program: summary of European data from 1997 to 2000.

Item
http://www.wikidata.org/entity/Q30668895
Extended-spectrum beta-lactamases and clinical outcomes: current data.Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems.Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems.Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital.Nosocomial urinary tract infections caused by extended-spectrum beta-lactamase uropathogens: Prevalence, pathogens, risk factors, and strategies for infection control.Characterization of the extended-spectrum β-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children.Widely distributed and predominant CTX-M extended-spectrum beta-lactamases in Amsterdam, The Netherlands.Prevalence of Plasmid-Mediated Quinolone Resistance Determinants and OqxAB Efflux Pumps among Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae Isolated from Patients with Nosocomial Urinary Tract Infection in Tehran, Iran.Prevalence and molecular characterization of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia.Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.Risk factors of mortality in bloodstream infections caused by Klebsiella pneumonia: A single-center retrospective study in China.Prevalence of Extended Spectrum β-lactamase-Producing Klebsiella pneumoniae in Clinical Isolates.Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.Characterization of extended-spectrum beta-lactamases in Enterobacteriaceae causing nosocomial infections in a Zagreb University Hospital.Susceptibility of bacterial isolates from Turkey--a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program.In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
P2860

MYSTIC program: summary of European data from 1997 to 2000.

Item
http://www.wikidata.org/entity/Q30668895
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
MYSTIC program: summary of European data from 1997 to 2000.
@ast
MYSTIC program: summary of European data from 1997 to 2000.
@en
type
label
MYSTIC program: summary of European data from 1997 to 2000.
@ast
MYSTIC program: summary of European data from 1997 to 2000.
@en
prefLabel
MYSTIC program: summary of European data from 1997 to 2000.
@ast
MYSTIC program: summary of European data from 1997 to 2000.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
MYSTIC program: summary of European data from 1997 to 2000.
@en
P2093
P304
P31
P356
10.1016/S0732-8893(01)00320-0
P433
P478
P577
P698